Redeye provides an update following CLS’s Q4 2025 report. Sales were disappointing during the quarter, driven by ongoing alignment discussions between CLS and ClearPoint Neuro. While these discussions could be positive in the long term, they create short-term uncertainty, prompting a slightly more cautious approach that lowers our sales expectations and updates our fair value range.
LÄS MER
